X4 Pharmaceuticals XFOR Stock
X4 Pharmaceuticals Price Chart
X4 Pharmaceuticals XFOR Financial and Trading Overview
| X4 Pharmaceuticals stock price | 0.2 USD |
| Previous Close | 2.41 USD |
| Open | 2.39 USD |
| Bid | 0 USD x 4000 |
| Ask | 0 USD x 2200 |
| Day's Range | 2.13 - 2.39 USD |
| 52 Week Range | 0.65 - 2.58 USD |
| Volume | 4.15M USD |
| Avg. Volume | 3.46M USD |
| Market Cap | 360.21M USD |
| Beta (5Y Monthly) | 0.259409 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.19 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.76 USD |
XFOR Valuation Measures
| Enterprise Value | 220.94M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.159091 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.3664303 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.323 |
Trading Information
X4 Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.259409 |
| 52-Week Change | 110.18% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.58 USD |
| 52 Week Low | 0.65 USD |
| 50-Day Moving Average | 1.7 USD |
| 200-Day Moving Average | 1.36 USD |
XFOR Share Statistics
| Avg. Volume (3 month) | 3.46M USD |
| Avg. Daily Volume (10-Days) | 2.86M USD |
| Shares Outstanding | 158.68M |
| Float | 100.89M |
| Short Ratio | 1.71 |
| % Held by Insiders | 0.65% |
| % Held by Institutions | 58.55% |
| Shares Short | 8.54M |
| Short % of Float | 7.00% |
| Short % of Shares Outstanding | 6.99% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -53.34% |
| Return on Equity (ttm) | -189.21% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -95098000 USD |
| Net Income Avi to Common (ttm) | -96209000 USD |
| Diluted EPS (ttm) | -0.87 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 93.41M USD |
| Total Cash Per Share (mrq) | 0.76 USD |
| Total Debt (mrq) | 36.93M USD |
| Total Debt/Equity (mrq) | 71.47 USD |
| Current Ratio (mrq) | 5.041 |
| Book Value Per Share (mrq) | 0.423 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -83385000 USD |
| Levered Free Cash Flow (ttm) | -48678248 USD |
Profile of X4 Pharmaceuticals
| Country | United States |
| State | MA |
| City | Boston |
| Address | 61 North Beacon Street |
| ZIP | 02134 |
| Phone | 857 529 8300 |
| Website | https://www.x4pharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 40 |
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Q&A For X4 Pharmaceuticals Stock
What is a current XFOR stock price?
X4 Pharmaceuticals XFOR stock price today per share is 0.2 USD.
How to purchase X4 Pharmaceuticals stock?
You can buy XFOR shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for X4 Pharmaceuticals?
The stock symbol or ticker of X4 Pharmaceuticals is XFOR.
Which industry does the X4 Pharmaceuticals company belong to?
The X4 Pharmaceuticals industry is Biotechnology.
How many shares does X4 Pharmaceuticals have in circulation?
The max supply of X4 Pharmaceuticals shares is 175.13M.
What is X4 Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
X4 Pharmaceuticals PE Ratio is now.
What was X4 Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
X4 Pharmaceuticals EPS is -0.19 USD over the trailing 12 months.
Which sector does the X4 Pharmaceuticals company belong to?
The X4 Pharmaceuticals sector is Healthcare.
X4 Pharmaceuticals XFOR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16708.05 USD — |
+2.5
|
7.57B USD — | 16642.66 USD — | 17029.86 USD — | — - | 7.57B USD — |
| NASDAQ Capital Market Composite RCMP | 100.7 USD — |
+1.49
|
— — | 100.43 USD — | 103.32 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 911.61 USD — |
+1.7
|
— — | 909.68 USD — | 929.8 USD — | — - | — — |
- {{ link.label }} {{link}}